HELP is trading 11% up at $5.65 after announcing a $50 million underwritten public offering of common shares to advance its mental health drug pipeline.
- The offering consists of 10,309,280 common shares priced at $4.85 per share, with the transaction expected to close on June 25, 2026.
- Capital raised will be used to fund key development programs, specifically the HLP003, HLP004, and HLP005 candidates in Helus Pharma’s pipeline.
- Market sentiment remains positive following yesterday’s pricing and today’s confirmation of the capital raise.